Novartis opens phase 1 study of HJB647 in uncontrolled hypertension
Novartis is advancing HJB647 into a first-in-human hypertension program with a randomized, double-blind, placebo-controlled phase 1 study in adults whose blood pressure remains elevated despite ongoing treatment. The protocol is built around a classic early-development question: can the compound be given safely, does it behave predictably in the body, and does the exposure profile support further dose selection?
The trial is enrolling adults with uncontrolled hypertension despite use of at least two antihypertensive medications. Participants must meet office-based blood pressure thresholds that keep the cohort firmly in the uncontrolled range, but not in a range that would immediately push the study into severe or unstable disease. Screening can last up to 30 days and includes a two-week participant-blinded placebo run-in, a design choice that helps filter out adherence noise and early expectation effects before randomization begins.
One sentence captures the study’s purpose plainly: this is a safety and pharmacokinetic trial, not an efficacy readout.
A staged design meant to protect participants while dose selection unfolds
The protocol uses a multicenter, randomized, participant- and investigator-blinded structure with two major stages. Arm 1 enrolls first, and investigators will review its safety and tolerability data before moving into either Arm 2a or Arm 2b. Only one of those follow-on arms will proceed, which means the development team is using early human data to choose between alternative regimens rather than exposing participants to every option at once.
That sequencing makes biological sense in a drug class moving through early development. In hypertension, even small shifts in vasodilation, sympathetic tone, renal sodium handling, or drug metabolism can create meaningful differences in blood pressure response and tolerability. A cautious stage-gated design reduces the chance that an unhelpful dose or exposure pattern is carried too far into later testing.
Participants are randomized in a 3:1 ratio to receive oral HJB647 or matching placebo while continuing background antihypertensive therapy. Keeping standard therapy in place is important: the trial is testing the investigational agent as an add-on in people whose blood pressure remains uncontrolled in real-world clinical practice, not as a replacement for established treatment.
Safety, electrocardiography, and laboratory change are the central early signals
The primary endpoint is straightforward: incidence and severity of adverse events and serious adverse events, including abnormal changes in vital signs, physical examinations, ECGs, and laboratory values that qualify and are reported as adverse events. Participants are followed from first dose through the arm-specific end-of-study visit, up to Day 85.
That endpoint matters because antihypertensive development can fail for reasons that have little to do with whether a molecule lowers pressure. Excessive hypotension, electrolyte disturbances, renal function changes, conduction abnormalities, and off-target toxicity can stop an otherwise plausible compound long before efficacy can be judged. In a population already taking multiple blood pressure drugs, safety margins must be defined with unusual care.
The exclusion criteria reflect that reality. Recent acute coronary syndrome, stroke, transient ischemic attack, aortic dissection, or major vascular procedures are excluded, as are clinically significant valvular disease, significant arrhythmias, New York Heart Association class II to IV heart failure, and recent hospitalization for hypertensive emergency or unstable uncontrolled hypertension. The protocol also excludes strong CYP3A4 inhibitors or inducers, soluble guanylate cyclase activators such as vericiguat, PDE5 inhibitors, and nitroglycerin products, all of which could complicate pharmacology or amplify hemodynamic risk.
Sex-specific QTcF cutoffs are also built into screening: 450 msec for men and 460 msec for women. That is a familiar safeguard in phase 1 work, especially for compounds that may alter autonomic tone, vascular function, or exposure to other medications.
Pharmacokinetics will help define exposure, not just dose
Secondary endpoints focus on pharmacokinetics, including maximum observed plasma concentration Cmax, time to maximum observed plasma concentration Tmax, and area under the plasma concentration-time curve over the dosing interval AUCtau, all assessed at protocol-specified time points through Day 64. Those measures will help define how much drug reaches the circulation, how quickly it peaks, and how long exposure persists across the dosing interval at steady state.
For a hypertension program, those data are more than academic. Blood pressure control often depends on whether exposure is sustained enough to blunt trough variability without creating peak-related adverse effects. A compound that looks acceptable in a short safety window may still prove impractical if its pharmacokinetics are too erratic, too short-lived, or too concentrated at the wrong time of day.
The study size is small, with an estimated enrollment of 24 participants, which is entirely consistent with a phase 1 objective. This cohort will not answer whether HJB647 reduces cardiovascular events, improves long-term blood pressure control, or offers any advantage over existing therapy. It will do something more limited and essential: establish whether the agent can be advanced with an acceptable early safety profile and interpretable exposure data.
Why this trial matters for patients with persistent hypertension
Uncontrolled hypertension remains a difficult clinical problem because many patients are already taking multiple medications by the time a new agent is considered. Some need additional blood pressure lowering, while others are limited by adverse effects, drug interactions, or the inability to intensify therapy further. A new oral agent that can be layered onto standard treatment only becomes meaningful if it clears the early hurdles of tolerability, predictable pharmacokinetics, and clean hemodynamic behavior.
The current protocol does not yet reveal the mechanism of HJB647, and it does not claim efficacy. Instead, it marks the beginning of human dose exploration in a carefully selected hypertensive population with built-in safeguards. The first question is whether the drug can be given without unacceptable toxicity. The second is whether the exposure profile justifies moving forward.
Estimated study start is November 23, 2026, with both primary completion and study completion projected for November 5, 2027. Until those data are available, the trial remains a blueprint for cautious development rather than evidence of therapeutic benefit.
Trial identifier and record details
The study is listed under NCT07940647 and carries the sponsor’s internal identifier CHJB647B12101. Novartis Pharmaceuticals is the sponsor and responsible party, and the record was first posted on November 17, 2026. The absence of results is expected at this stage; the work ahead is to determine whether early human exposure to HJB647 is compatible with further hypertension development.
- • ClinicalTrials.gov Trial Protocol (NCT07940647): https://clinicaltrials.gov/study/NCT07940647